PL2054040T3 - Sposób wytwarzania stałych dyspersji midostauryny - Google Patents

Sposób wytwarzania stałych dyspersji midostauryny

Info

Publication number
PL2054040T3
PL2054040T3 PL07811314T PL07811314T PL2054040T3 PL 2054040 T3 PL2054040 T3 PL 2054040T3 PL 07811314 T PL07811314 T PL 07811314T PL 07811314 T PL07811314 T PL 07811314T PL 2054040 T3 PL2054040 T3 PL 2054040T3
Authority
PL
Poland
Prior art keywords
solid dispersions
midostaurin
making solid
highly crystalline
compounds
Prior art date
Application number
PL07811314T
Other languages
English (en)
Inventor
Indrajit Ghosh
Jennifer Snyder
Wei-Qin Tong
Sudha Vippagunta
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2054040T3 publication Critical patent/PL2054040T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL07811314T 2006-08-16 2007-08-14 Sposób wytwarzania stałych dyspersji midostauryny PL2054040T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82255606P 2006-08-16 2006-08-16
PCT/US2007/017960 WO2008021347A2 (en) 2006-08-16 2007-08-14 Method for making solid dispersions of highly crystalline therapeutic compounds
EP07811314A EP2054040B1 (en) 2006-08-16 2007-08-14 Method for making solid dispersions of midostaurin

Publications (1)

Publication Number Publication Date
PL2054040T3 true PL2054040T3 (pl) 2011-09-30

Family

ID=38657762

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07811314T PL2054040T3 (pl) 2006-08-16 2007-08-14 Sposób wytwarzania stałych dyspersji midostauryny

Country Status (16)

Country Link
US (2) US20100038816A1 (pl)
EP (1) EP2054040B1 (pl)
JP (1) JP5546860B2 (pl)
KR (1) KR101462693B1 (pl)
CN (1) CN101516339B (pl)
AT (1) ATE503484T1 (pl)
AU (1) AU2007284615B2 (pl)
BR (1) BRPI0714963A2 (pl)
CA (1) CA2660086C (pl)
DE (1) DE602007013567D1 (pl)
ES (1) ES2363725T3 (pl)
MX (1) MX2009001636A (pl)
PL (1) PL2054040T3 (pl)
PT (1) PT2054040E (pl)
RU (1) RU2454220C2 (pl)
WO (1) WO2008021347A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009134848A1 (en) * 2008-04-30 2009-11-05 Novartis Ag Continuous process for making pharmaceutical compositions
EP2327706A1 (en) 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN102525879B (zh) * 2010-12-31 2015-01-21 正大天晴药业集团股份有限公司 制备阿瑞匹坦固体分散组合物的方法
EP3122799B8 (en) 2014-03-25 2020-03-11 F.Hoffmann-La Roche Ag Methods of preparing a poloxamer for use in cell culture medium
WO2016100147A1 (en) 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
BR112018003209B1 (pt) 2015-08-20 2021-07-13 Unilever Ip Holdings B.V. Composição compreendendo uma lactama e um lactato de alquila ou alquenila
WO2017029104A1 (en) 2015-08-20 2017-02-23 Unilever Plc Process for the preparation of lactams from glyoxylic acid
CN117338617A (zh) 2015-08-20 2024-01-05 联合利华知识产权控股有限公司 改善的内酰胺溶解度
EP3337451B1 (en) 2015-08-20 2018-12-26 Unilever PLC Improved lactam solubility
EP3337452B1 (en) 2015-08-20 2024-03-27 Unilever IP Holdings B.V. Encapsulated lactams
US10888087B2 (en) 2015-08-20 2021-01-12 Conopco, Inc. Lactam solubility
CN107847416B (zh) * 2015-08-20 2021-07-20 荷兰联合利华有限公司 分散的内酰胺
KR20190003945A (ko) * 2016-03-24 2019-01-10 로케이트 테라퓨틱스 리미티드 스캐폴딩 물질, 방법 및 용도
US11510986B2 (en) * 2016-05-13 2022-11-29 Merck Patent Gmbh Hot melt extrusion composition using direct compressible excipient as plasticizer
AU2019215127A1 (en) 2018-02-01 2020-06-18 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
US20190231783A1 (en) * 2018-02-01 2019-08-01 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
JP7211644B2 (ja) 2019-02-18 2023-01-24 スレイバック・ファーマ・エルエルシー ニロチニブの医薬組成物
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN114796149A (zh) * 2022-04-27 2022-07-29 苏州中化药品工业有限公司 一种高生物利用度的双醋瑞因胶囊剂及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5837714A (en) * 1997-03-03 1998-11-17 Sanofi Solid pharmaceutical dispersions
JP2001520984A (ja) * 1997-10-27 2001-11-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 水難溶性薬剤の固態溶剤及び固体分散体
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
EP1372611B1 (en) * 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
JP4101661B2 (ja) * 2001-05-03 2008-06-18 エフ．ホフマン−ラ ロシュ アーゲー 非晶質メシル酸ネルフィナビルの製薬剤形
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
US6482830B1 (en) * 2002-02-21 2002-11-19 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
WO2005020913A2 (en) * 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
AR047948A1 (es) * 2003-11-21 2006-03-15 Schering Corp Formulaciuones de inhibidores de la fosfodiesterasa v
US7498309B2 (en) * 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
CN102127053A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
US20050288481A1 (en) * 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
AU2005279344B2 (en) * 2004-08-31 2009-11-12 Novartis Ag Use of midostaurin for treating gastrointestinal stromal tumors
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JO2897B1 (en) * 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
EP1819319A1 (en) * 2004-12-02 2007-08-22 Warner-Lambert Company LLC Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
PL1962808T3 (pl) * 2005-12-14 2011-03-31 Hoffmann La Roche Preparat proleku przeciw HCV
EP2201840B1 (en) * 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
US8258137B2 (en) * 2008-01-29 2012-09-04 Katholieke Universiteit Leuven Process for release of biologically active species from mesoporous oxide systems
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
CA3113343A1 (en) * 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
CA2811601A1 (en) * 2010-09-24 2012-03-29 Mallinckrodt Llc Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
US9295673B2 (en) * 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

Also Published As

Publication number Publication date
WO2008021347A2 (en) 2008-02-21
US20120190667A1 (en) 2012-07-26
MX2009001636A (es) 2009-02-23
PT2054040E (pt) 2011-06-30
WO2008021347A3 (en) 2008-08-07
EP2054040A2 (en) 2009-05-06
US20100038816A1 (en) 2010-02-18
CA2660086C (en) 2014-09-16
AU2007284615B2 (en) 2011-10-27
CN101516339A (zh) 2009-08-26
US8641948B2 (en) 2014-02-04
RU2009109357A (ru) 2010-09-27
RU2454220C2 (ru) 2012-06-27
ES2363725T3 (es) 2011-08-12
KR20090042961A (ko) 2009-05-04
KR101462693B1 (ko) 2014-11-17
DE602007013567D1 (de) 2011-05-12
AU2007284615A1 (en) 2008-02-21
JP5546860B2 (ja) 2014-07-09
EP2054040B1 (en) 2011-03-30
CN101516339B (zh) 2012-06-13
CA2660086A1 (en) 2008-02-21
JP2010500411A (ja) 2010-01-07
ATE503484T1 (de) 2011-04-15
BRPI0714963A2 (pt) 2013-07-30

Similar Documents

Publication Publication Date Title
PL2054040T3 (pl) Sposób wytwarzania stałych dyspersji midostauryny
EP1950177A4 (en) SEMICONDUCTOR THIN FILM, MANUFACTURING METHOD AND THIN FILM TRANSISTOR
GB0816666D0 (en) Semiconductor field effect transistor and method for fabricating the same
EP1873847A4 (en) CATHODE ACTIVE MATERIAL AND METHOD OF MANUFACTURING THE SAME
EP1872408A4 (en) HIGH ELECTRONIC MOBILITY GAN-BASED TRANSISTOR AND METHOD FOR MANUFACTURING THE SAME
EP2117040A4 (en) COMPOUND SEMICONDUCTOR DEVICE AND METHOD FOR MANUFACTURING THE SAME
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
EP1921049A4 (en) POLYCRYSTALLINE DIAMOND WITH HIGH HARDNESS AND METHOD OF MANUFACTURING THEREOF
EP2111642A4 (en) ORGANIC TRANSISTOR AND MANUFACTURING METHOD THEREFOR
TWI318798B (en) Organic thin film transistor and method for manufacturing the same
EP1845101A4 (en) PROCESS FOR PREPARING AN ALKOXYTITANE COMPLEX
EP1939319A4 (en) SEMICONDUCTOR THIN FILM AND METHOD FOR PRODUCING THE SAME
EP1873194A4 (en) PROCESS FOR PRODUCING POLYOLEFIN MICROPOROUS FILM AND MICROPOROUS FILM
SI1926476T1 (sl) Amorfne trdne disperzije 7-kloro-N,N,5-trimetil-4-okso-3-fenil-3,5- dihidro-4H-piridazino/4,5-b/indol-1-acetamida
EP1873158A4 (en) CRYSTALS OF A MORPHINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF
EP1935883A4 (en) OXINDOL DERIVATIVES AS A MEANS FOR CONTROLLING FOOD RECEPTION
IL181832A0 (en) Alkylidene tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents
DK1691086T3 (da) Isolationsmaterialebeholder
PL374461A1 (pl) Sposób otrzymywania pochodnych 13,14-dihydro-PGF
GB0915454D0 (en) Novel benzothiazole and benzoxazole linked pyrrolo (2,1-C) (1,4) benzodiazepine hybrids as novel antitumour agents and process for the preparation thereof
EP2065915A4 (en) DIAMOND ELECTRON SOURCE AND METHOD FOR MANUFACTURING SAME
IL185335A0 (en) Process for the preparation of substituted benzoxazole compounds
AU2008306604A8 (en) Process for the preparation of zolmitriptan, salts and solvates thereof
EP2006404A4 (en) EXAMPLE OF ALUMINUM 6000 EXCELLENT IN TERMS OF PAINT COOKING TEMPERATURE AND PROCESS FOR PRODUCING THE SAME
GB0515025D0 (en) Organic compounds